Clinical Trial Update: JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating JCAR014 in combination with Durvalumab for relapsed or refractory B-cell non-Hodgkin lymphoma has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High Grade B-cell Lymphoma with Myc Bcl2 and Bcl6 Rearrangements
• Mediastinal Large B-cell Lymphoma
• Not Otherwise Specified Diffuse Large B-cell Lymphoma

Drugs mentioned

• Durvalumab (durvalumab)
• JCAR014

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2022-08-24